NFKB1 and glioblastoma: Remarkably, PDGFR-β knockout in ECs robustly sensitizes GBM tumors to anti-VEGF therapy, suggesting targeting PDGF/NF-κB/Snail axis and preventing Endo-MT in ECs may offer exciting opportunities in antiangiogenic therapy resistance.